BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma. J Hepatol 2022;77:849-64. [PMID: 35594992 DOI: 10.1016/j.jhep.2022.04.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Z, Liu H, Chen Z, Deng C, Zhou L, Chen S, Kang J, Chen Y, He S, Zhou Z. Identification of a novel plasma metabolite panel as diagnostic biomarker for hepatocellular carcinoma. Clin Chim Acta 2023;:117302. [PMID: 36940842 DOI: 10.1016/j.cca.2023.117302] [Reference Citation Analysis]
2 Oliviero B, Cas MD, Zulueta A, Maiello R, Villa A, Martinelli C, Favero ED, Falleni M, Montavoci L, Varchetta S, Mele D, Donadon M, Soldani C, Franceschini B, Maestri M, Piccolo G, Barabino M, Bianchi P, Banales JM, Mantovani S, Mondelli M, Caretti A. Ceramide present in cholangiocarcinoma-derived extracellular vesicle induces a pro-inflammatory state in monocytes.. [DOI: 10.21203/rs.3.rs-2499429/v1] [Reference Citation Analysis]
3 Li X, Zhang C, Wu E, Han L, Deng X, Shi Z. UPLC-Q-TOF/MS-Based Metabolomics Approach Reveals Osthole Intervention in Breast Cancer 4T1 Cells. Int J Mol Sci 2023;24. [PMID: 36674685 DOI: 10.3390/ijms24021168] [Reference Citation Analysis]
4 Xu L, Gao X, Xing J, Guo Z. Identification of a necroptosis-related gene signature as a novel prognostic biomarker of cholangiocarcinoma. Front Immunol 2023;14:1118816. [PMID: 36936916 DOI: 10.3389/fimmu.2023.1118816] [Reference Citation Analysis]
5 Song J, Zhang L, Song B, Yang G. Tailoring adipose stem cells towards high therapeutic performance: Perspectives in manipulation and manufacturing. Chemical Engineering Journal 2023;456:141020. [DOI: 10.1016/j.cej.2022.141020] [Reference Citation Analysis]
6 Thamrongwaranggoon U, Kuribayashi K, Araki H, Hino Y, Koga T, Seubwai W, Wongkham S, Nakao M, Hino S. Lactic acidosis induces metabolic and phenotypic reprogramming in cholangiocarcinoma cells via the upregulation of thrombospondin-1. Cancer Sci 2022. [PMID: 36562400 DOI: 10.1111/cas.15699] [Reference Citation Analysis]
7 Chen J, Yu X, Tong H, Tang C, Tang Z. Establishment and experimental validation of a novel cuproptosis-related gene signature for prognostic implication in cholangiocarcinoma. Front Oncol 2022;12:1054063. [PMID: 36568224 DOI: 10.3389/fonc.2022.1054063] [Reference Citation Analysis]
8 Qiu S, Wang Y, Rao H, Que Q, Wu Y, Zhu R, Feng X, Chi J, Lai W, Sun Y, Xiao Q, Shi H, Xiang Y. Tumor microenvironment-associated lactate metabolism regulates the prognosis and precise checkpoint immunotherapy outcomes of patients with lung adenocarcinoma. Eur J Med Res 2022;27:256. [PMID: 36411477 DOI: 10.1186/s40001-022-00895-6] [Reference Citation Analysis]
9 Luo Y, Deng F, Zhang Y, Xiao Y. Editorial: Molecular biomarkers and imaging markers in the prediction, diagnosis, and prognosis of bladder cancer. Front Cell Dev Biol 2022;10:1014565. [DOI: 10.3389/fcell.2022.1014565] [Reference Citation Analysis]
10 Wu W, Pu Y, Zhou B, Shen Y, Gao S, Zhou M, Shi J. Photoactivatable Immunostimulatory Nanomedicine for Immunometabolic Cancer Therapy. J Am Chem Soc 2022. [PMID: 36215038 DOI: 10.1021/jacs.2c07872] [Reference Citation Analysis]
11 Wu H, Wang M, Zhu J, Li Z, Wang W, Gu L, Shen F, Yang T. Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine. Pharmaceutics 2022;14:1760. [DOI: 10.3390/pharmaceutics14091760] [Reference Citation Analysis]